Home    Back

Simvastatin susp.    (DrugBank: Simvastatin)

1 disease
IDDisease name (Link within this page)Number of trials
310Congenital anomalies syndrome1

310. Congenital anomalies syndrome    [ 10 clinical trials,   18 drugs,   (DrugBank: 10 drugs),   3 drug target genes,   7 drug target pathways]
Searched query = "Congenital anomalies syndrome", "Trisomy 1q", "9q34 deletion syndrome", "Cornelia de Lange syndrome", "CdLS", "Smith-Lemli-Opitz syndrome", "SLO syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 10 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00064792
(ClinicalTrials.gov)		July 200311/7/2003Simvastatin Therapy in Smith-Lemli-Opitz SyndromeInvestigation of Simvastatin Therapy in Smith-Lemli-Opitz SyndromeSmith-Lemli-Opitz SyndromeDrug: Simvastatin Susp.;Drug: OraPlusForbes Porter, M.D.Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Completed4 Years18 YearsAll23Phase 2United States